References and thanks for the kidney cancer information section

References

The information in the kidney cancer information section was produced in accordance with the following sources and guidelines. We’ve listed a sample of the sources used here below. If you’d like further information about the sources we use, please contact us|.

• European Society for Medical Oncology (ESMO). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010.
• Guidelines on Renal Cell Carcinoma. European Association of Urology. 2010.
• NICE Interventional Procedure Guideline. Percutaneous cryotherapy for renal tumours. National Institute for Health and Clinical Excellence (NICE). July 2011.
• NICE Interventional Procedure Guideline. Percutaneous radiofrequency ablation of renal cancer. National Institute for Health and Clinical Excellence (NICE). July 2010.  
• NICE Technology Appraisal Guidelines. Bevacizumab (first-line), sorafenib (first-and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. National Institute for Health and Clinical Excellence (NICE). August 2009.
• NICE Technology Appraisal Guideline. Everolimus for the second-line treatment of advanced renal cell carcinoma. National Institute for Health and Clinical Excellence (NICE). April 2011.
• NICE Technology Appraisal Guideline. Pazopanib for the first line treatment of metastatic renal cell carcinoma. National Institute for Health and Clinical Excellence (NICE). February 2011.

Thanks

With thanks to: Dr Rosalie Fisher, Clinical Research Fellow; Dr James Larkin, Consultant in Oncology; Dr Louise Lim, Medical Oncology Registrar; Dr Vinod Nargund, Consultant Urological Surgeon; and Debbie Victor, Uro-Oncology Clinical Nurse Specialist.

 

Thanks to people like you

Thank you to all of the people affected by cancer who reviewed what you're reading and have helped our information to grow.

You could help us too when you join our Cancer Voices Network - find out more|.